Research & Development



  如果是雲瑯,他自然會毫無保留的告訴他皇帝正在看他們家的書,而且已經看了不下十年。   這對羌人們來說是一件天大的事情,很早以前,就有人提出過這個想法,只是因為匈奴人不喜歡城池這種可以阻擋馬蹄的東西,建城的建議一次又一次的被束之高閣。2014体育彩票休市   “這該有十斤吧?”2013福利彩票开奖79期   隋越笑道︰“這是四年前新換的,來自嶺南。”   這是秋日里的最後一茬西瓜,是雲氏款待嘉賓的好東西,同時也是皇室規定的貢品。2013彩票充20送20   那些因為貢獻不純黃金給太廟的罪官,全部得到了赦免,甚至官職都沒有褫奪,被拿走的僅僅是封地跟爵位。

Our discovery and development platforms for drug and cell-based therapies allow us to both create and retain significant value within our therapeutic franchise areas of cancer and inflammatory diseases. Scientists and physicians at Celgene are the driving force behind our success, enabling target-to-therapeutic platforms that integrate both small-molecule and cell-based therapies.

Connect? Registries

The Connect??Registries are observational, hematologic patient registry studies in Multiple Myeloma (Connect?MM), Chronic Lymphocytic Leukemia (Connect?CLL) and Myelodysplastic Syndromes/Acute Myeloid Leukemia (Connect?MDS/AML) and are sponsored by Celgene Corporation. These studies are designed to observe the routine care of patients through the course of their disease. Unlike clinical trials, registries do not require or provide any specific medications or healthcare services, but leave those decisions to the treating doctors and their patients.
Connect? Registries logo